In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of 10x Genomics Inc (NASDAQ: TXG) closed at $11.29 in the last session, up 3.58% from day before closing price of $10.90. In other words, the price has increased by $3.58 from its previous closing price. On the day, 3.5 million shares were traded.
Ratios:
We take a closer look at TXG’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.26 and its Current Ratio is at 4.97. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on February 13, 2025, Downgraded its rating to Market Perform and sets its target price to $12 from $25 previously.
On September 03, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $35.
Jefferies Upgraded its Hold to Buy on July 22, 2024, while the target price for the stock was maintained at $24.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 24 ’25 when Saxonov Serge bought 5,104 shares for $11.56 per share.
Hindson Benjamin J. bought 4,563 shares of TXG for $52,748 on Feb 24 ’25. On Nov 22 ’24, another insider, Saxonov Serge, who serves as the Chief Executive Officer of the company, sold 6,693 shares for $13.69 each. As a result, the insider received 91,612 and left with 872,574 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.26 while its Price-to-Book (P/B) ratio in mrq is 1.94.
Stock Price History:
Over the past 52 weeks, TXG has reached a high of $48.42, while it has fallen to a 52-week low of $10.80. The 50-Day Moving Average of the stock is -21.14%, while the 200-Day Moving Average is calculated to be -38.39%.
Shares Statistics:
A total of 108.24M shares are outstanding, with a floating share count of 101.42M. Insiders hold about 17.08% of the company’s shares, while institutions hold 79.45% stake in the company.
Earnings Estimates
The current rating of 10x Genomics Inc (TXG) reflects the combined expertise of 2.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.1 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.52 and -$0.55 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.42, with 2.0 analysts recommending between -$0.37 and -$0.47.
Revenue Estimates
According to 15 analysts, the current quarter’s revenue is expected to be $133.55M. It ranges from a high estimate of $147.9M to a low estimate of $121.3M. As of the current estimate, 10x Genomics Inc’s year-ago sales were $141.01MFor the next quarter, 15 analysts are estimating revenue of $146.4M. There is a high estimate of $153.8M for the next quarter, whereas the lowest estimate is $136.67M.
A total of 16 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $627.1M, while the lowest revenue estimate was $599.58M, resulting in an average revenue estimate of $612.62M. In the same quarter a year ago, actual revenue was $610.78MBased on 16 analysts’ estimates, the company’s revenue will be $668.89M in the next fiscal year. The high estimate is $687.37M and the low estimate is $646.39M.
